Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Internis Pharmaceuticals

Internis Pharmaceuticals
2010 FOUNDED
M&A STATUS
31-40 EMPLOYEES
M&A LATEST DEAL TYPE
$76.8M LATEST DEAL AMOUNT
Description

Provider of vitamin D medicines. The company is engaged in the development and commercialization of medicines for the treatment of bone disorders like osteoporosis and vitamin D3 deficiency.

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Other Healthcare Services
Other Industries
Pharmaceuticals
Parent Company
Primary Office
  • Linthwaite Laboratories
  • West Yorkshire
  • Huddersfield HD7 5QH
  • England, United Kingdom

+44 01484 000000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Internis Pharmaceuticals’s full profile, request a free trial.

Internis Pharmaceuticals Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 19-Dec-2014 $76.8M 00.000 000.00 Completed Startup
1. Debt - General 10-Sep-2013 00.000 00.000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Internis Pharmaceuticals Executive Team (3)

Name Title Board
Seat
Contact
Info
Charles Tannenbaum Co-Founder & Co-Chief Executive Officer
Martin Knight Co-Founder & Director
Alan Walker Ph.D Chief Executive Officer